API manufacturing

Eli Lilly will turn Huntsville, Alabama into the domestic hub for small‑molecule and peptide API production, investing more than $6 billion in a next‑generation facility that will manufacture its first oral GLP‑1 agonist, orforglipron. Construction begins in 2026, creating about 3,000 temporary jobs, and the plant—set to finish in 2032—will support 450 high‑skill positions. The site employs AI‑driven automation, aims for carbon‑neutral operations, and complements Lilly’s broader U.S. expansion to bolster supply‑chain resilience and domestic drug manufacturing.